Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer

Inclusion Criteria

• •Patients must have had NSCLC.
• •Patients must have received erlotinib (single-agent) for six months or longer for NSCLC in the second/third line setting or as maintenance therapy.
• •Patients must have tissue available for EGFR-mutation status testing (if not previously performed) or EGFR-mutation status test results available.
• •Patients must have tissue available for exploratory genetic analysis.
• •Patients must have all clinical information, treatment response data and outcomes data available for review.
• •Patients must be deceased.